Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
39°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Can-Fite BioPharma Ltd.
< Previous
1
2
3
Next >
Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit
May 02, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis Drug
April 05, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022
March 28, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Reports 2021 Financial Results & Provides Clinical Update
March 24, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite: Namodenoson’s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office
March 14, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson
January 31, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Prior to Phase III Psoriasis Data Release Can Fite Reports that Piclidenoson Destroys Pathological Skin Cells in vitro
January 13, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference
January 10, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Issues Letter to Shareholders
January 05, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid Tumors
December 29, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study
December 20, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite’s Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022
December 07, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021
November 24, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite’s Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis
November 23, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite to Present at H.C. Wainwright 7th Annual Israel Conference
November 12, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite’s Findings on Cannabis Compound’s Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLD’s The Liver Meeting® 2021 Conference
November 01, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite’s NASH Patents Granted and Allowed in Japan, Hong Kong, and Mexico
October 28, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite CEO to Present Namodenoson’s Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit
October 26, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal
October 21, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite to Present at H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021
October 05, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite CEO to Join Benzinga Medical Cannabis Panel and Deliver Company Presentation at Healthcare Small Cap Conference on September 29, 2021
September 22, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite to Participate in Three Upcoming Pharma Partnering Conferences
September 17, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study
September 02, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Reports Second Quarter 2021 Financial Results & Provides Clinical Update
August 26, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Announces $10.0 Million Registered Direct Offering
August 12, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Yossi Borenstein, CEO and Founder of Shizim Group, has been Elected to the Can-Fite Board
August 05, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study
July 08, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Enters Projected $3 Billion Veterinary Osteoarthritis Market: Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets
June 28, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Receives Notice of Patent Allowance in China for NASH Treatment
June 16, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.